Warning: Constant WP_CACHE already defined in /home/bicollgroup/public_html/wp-config.php on line 8
Company News - Bicoll GmbH

Bicoll News

Declining Biodiversity – A Threat to Future Pharmaceutical Development

China is home to Artemisia annua, a herb that has been used in traditional medicine for almost 2,000 years. Its main active compound, artemisinin, has been found to be very effective as treatment against resistant malaria. Since 2001, the World Health Organisation (WHO) has recommended to switch to an
artemisinin-based combination therapy in countries where conventional malaria drugs have failed. Much like this example, scientists in the pharmaceutical development field are also often inspired by natural products in their research programs. They hope to develop tomorrow’s medical break-throughs by discovering Nature’s secrets.

Read more

Bioperspectives 2005

Dr. Christian Haug talks about “Added value through know-how networks” at BioPerspectives 2005, Wiesbaden/Germany.

DECHEMA: Set-up of a research location in Shanghai

Dr. Christian Haug talks about “Set-up of a research location in Shanghai” at DECHEMA Conference Day “Research and Development in China“, Frankfurt a.M./ Germany. Program here.  

Bicoll – Positive Bilanz

Die Bicoll GmbH hat laut eigenen Angaben das abgelaufene Geschäftsjahr mit einem Gewinn abgeschlossen. Bereits drei Jahre nach der Gründung weise das Unternehmen nach Abzug von Steuern eine positive Bilanz auf. Bicolls Hauptprodukte sind optimierte Substanz-Bibliotheken für
die Wirkstoffidentifizierung in der biopharmazeutischen Industrie.

Read more

Bicoll in profit after three years

Bicoll in profit after three years Sino-German biotech Bicoll (Shanghai/Munich) has generated
its maiden after-tax profit in only its third year of operations. The firm, which specialises in high-tech natural product chemistry, has five strategic customers for its optimised small molecule libraries (known as Bilobac N) for drug discovery. Using its technology, including prediction toolbox Bipreselect,
Bicoll tests and develops its libraries for fees and milestone payments as well as working on in-house projects (BVV Vol 17, No 17, p13). This financial milestone places Bicoll “in a stable position from where we can target our second phase of growth to release the full potential of the company”, commented managing director Dr Kai Lamottke.

Read more